Search This Blog

Friday, July 17, 2020

Luminex up 9% on emergency use nod for COVID-19 blood test

Luminex (LMNX +9.3%) is up 15% higher volume on the heels of U.S. emergency use authorization for its xMAP SARS-CoV-2 IgG antibody test.
In April, it received the emergency use nod for its test that detects the presence of the coronavirus.

J&J gene therapy shows encouraging action in vision loss disorder

Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies reports positive six-month data from a Phase 1/2 clinical trial evaluating gene therapy AAV-RPGR in patients with X-linked retinitis pigmentosa, a group of inherited retinal disorders characterized by progressive vision loss.
Preliminary results showed that low and intermediate doses were generally well-tolerated and indicated significant improvements in vision.
A pre-recorded webcast on the data is available via http://www.investor.jnj.com and selecting “Webcasts/Presentations.”
Development is ongoing.

Sanofi Looking at US Biotech Acquisitions

Sanofi SA is looking at potential U.S. biotech acquisitions as it seeks to expand its work in multiple sclerosis and immune disorders, Bloomberg reports, citing unnamed sources.
–One of the targets being studied by the French company is Pricipia Biopharma Inc., Bloomberg reports.

UK to review potentially faulty England COVID-19 death data

Health Minister Matt Hancock ordered a review into how England reports coronavirus deaths, after academics said the daily figures may include people who have died of other causes.    The way Public Health England, a government agency responsible for managing infectious disease outbreaks, calculates the figures means they might look worse there than in other parts of the United Kingdom, according to two academics.
Britain has been the European country worst hit by the virus, with an official death toll of more 45,000. But the government has said international comparisons are misleading because countries record coronavirus deaths differently.
Yoon Loke, from the University of East Anglia, and Carl Heneghan, from the University of Oxford, said Public Health England cross-checks the latest notifications of deaths against a database of positive test results – so anyone who has tested positive can be recorded as dying from the virus.
“Matt Hancock is going to be doing a review of those statistics with Public Health England,” Prime Minister Boris Johnson told a media conference on Friday.
In a blog called “Why no-one can recover from COVID-19 in England”, the academics said that patients who tested positive for coronavirus, but are successfully treated, will still be counted as dying from the virus “even if they had a heart attack or were run over by a bus three months later”.
The academics said this was the reason why England’s death figures vary substantially from day to day.
The same approach is not used in other parts of the United Kingdom. In Scotland, there is a 28-day cut-off, after which a patient who has tested positive is not automatically considered to have died from the virus.
Office for National Statistics figures on excess deaths in Britain show more than 64,000 people have died than usual during the coronavirus pandemic. Many health experts focus on those rather than the official COVID-19 toll.

ALX Oncology prices IPO at $19

ALX Oncology (ALXO) has priced its IPO of 8.5M common shares at $19.00/share, for expected gross proceeds of $161.5M.
Underwriters’ over-allotment is an additional 1,275,000 shares.
Trading kicks off on July 17.
Closing date is July 21.

Deerfield Healthcare prices IPO at $10

Deerfield Healthcare Technology Acquisitions (DFHT) has priced its IPO of 12.5M units at $10.00/unit.
Common shares trading kicks off on July 17.
Closing date is July 21.

Pandion Therapeutics prices IPO at $18

Pandion Therapeutics (PAND) has priced its IPO of 7.5M common shares at $18 per share.
Underwriters’ over-allotment is an additional ~1.1M shares. Closing date is July 21.
Trading kicks off today.